牛骨形成蛋白在骨不连中的临床应用

应用牛骨形成蛋白（ｂｏｖｉｎｅＢｏｎｅＭｏｒｐｈｏｇｅｎｅｔｉｃＰｒｏｔｅｉｎ简称ｂ－ＢＭＰ）成功的治愈１３例骨不连病人。经过１３个月～２９个月随访观察，效果较好。本组病人术前平均已做过１．５次手术。１３例病人中，有１２例被１次治愈。１例病人再次行内固定加用牛骨形成蛋白的植入也被治愈。骨形成蛋白的应用方式，采用同锻石膏复合后植入骨不连处。平均每个病人植入１００ｍｇＢＭＰ，１３例病人平均治愈时间为４．７个月。术后没有任何并发症。     

自制消定橡皮膏临床疗效观察

为观察自制消定橡皮膏的疗效，经538例患者临床治疗，结果治愈342例，有效181例，无效15例，总有效率97．21％。提示消定橡皮膏确有化瘀、消肿、止痛之功效。     

重组人干扰素α2b雾化吸入联合远红外止咳贴治疗小儿毛细支气管炎的临床效果

目的观察重组人干扰素α2b雾化吸入联合远红外止咳贴治疗毛细支气管炎的效果。方法选取2018年3月至2020年3月玉林市妇幼保健院收治的80例毛细支气管炎患儿,采用随机数字表法分为观察组与对照组,每组各40例。对照组给予常规综合治疗,观察组在常规综合治疗的基础上给予氧气驱动雾化吸入α2b干扰素联合远红外止咳贴治疗。比较两组治疗后的临床疗效、临床症状消失时间、住院时间以及肺部功能。结果观察组临床总有效率高于对照组,差异有统计学意义(P<0.05);观察组喘憋消失时间、咳嗽消失时间、肺部啰音消失时间、体温恢复正常时间、住院时间均短于对照组,差异有统计学意义(P<0.05);观察组治疗后潮气量、达峰时间比、达峰容积比均高于对照组,差异有统计学意义(P<0.05)。结论雾化吸入干扰素α2b联合远红外止咳贴治疗毛细支气管炎对提高治疗有效率,缩短临床症状消失时间、住院时间,改善肺功能具有重要作用,值得临床推广使用。     

跟后石膏托加小夹板治疗踝部内翻骨折脱位

目的：探讨踝关节内翻型骨折脱位中国接骨法的新疗法。方法：用手法复位，跟后石膏托加小夹板外固定早期练功，并系统观察21例。结果：骨折愈合时间8周，随访17例功能优良者占88％，较手术疗法愈合时间短，功能恢复好。较袜套牵引法减少了卧床。     

四肢长骨病理性骨折的治疗

目的分析石膏托和交锁髓内钉治疗股骨、胫骨、肱骨、桡骨病理性骨折的疗效。方法30例病理骨折(26例骨折、4例临界骨折)采用交锁髓内钉治疗,9例采用石膏托外固定。6例良性病变行病灶刮除、自体和(或)异体骨移植;15例转移癌13例行病灶姑息切除、骨水泥填充加强,2例单纯闭合穿钉固定。结果6例良性病变患者获随访,骨折首次术后平均4.5个月愈合;因复发或内固定失败需再手术2例。15例转移癌获随访,疼痛缓解功能恢复满意。结论交锁髓内钉是治疗股骨、胫骨、肱骨病理性骨折理想的内固定物,外固定可缓解疼痛,但有关节僵硬等并发症。     

祛瘀消痛贴膏治疗癌性腹痛疗效观察

目的:观察祛瘀消痛贴膏治疗癌性腹痛的临床疗效及意义。方法:采用活血化瘀、散结止痛的中药止痛膏治疗癌性腹痛110例,观察患者止痛起效时间、持续时间、疗效和副作用。结果:用药7天,110例中CR 21例(19.09%),PR47例(42.73%),MR 30例(27.27%),NR 12例(10.91%),总有效率89.09%;起效时间最短1h,最长3h,平均起效时间1.5h。每副贴膏持续止痛时间最长可达24h,总无痛持续时间最短为4天,最长为7天。结论:祛瘀消痛贴膏治疗癌性腹痛副作用小、疗效可靠,值得进一步推广。     

Exercise handout and one-on-one hand therapy for management of stiffness after plaster cast immobilization of simple phalangeal and metacarpal fractures in children: A randomized,noninferiority trial

Study DesignThis is a noninferior, single-blind, randomized controlled trial.IntroductionJoint stiffness is common after plaster cast immobilization for simple phalanx and metacarpal fractures in children. The limited literature suggests this joint stiffness in children resolves without one-on-one therapy; however, without robust studies confirming that there is no detrimental effect from withdrawing treatment, many children are still referred.Purpose of the StudyThe purpose of this study was to determine if an educational handout for self-management of stiffness is noninferior to one-on-one hand therapy for achieving full range of motion (ROM).MethodsParticipants were randomly assigned to group one who received the handout or group two who received hand therapy in addition to the handout. The ROM was measured by composite flexion and total active motion (TAM). The noninferiority margin was 10% difference between the two groups in the proportion of participants who achieved full ROM at two weeks after cast removal.ResultsSixty participants in each group completed the study. Group difference for composite flexion was 1.7% (95% CI: −3.9% to 7.2%), demonstrating noninferiority. Group difference for TAM was inconclusive at 8.3% (95% CI: −2.1% to 18.7%). Sensitivity analysis adjusting for participants with full composite flexion at the baseline resulted in the group difference for composite flexion of 3.1% (95% CI: −3.6% to 9.8%), maintaining noninferiority, but group difference for TAM at 10.4% (95% CI: 0.0% to 20.9%), was inconclusive with the handout group significantly worse.ConclusionAn educational handout is noninferior to hand therapy for achieving full ROM in composite flexion but not TAM. This needs to be taken into consideration for changing clinical practise.     

Litigation related to casting in Orthopaedics—An analysis of claims against the National Health Service in England

Orthopaedic casts have been used to treat musculoskeletal conditions for hundreds of years and are still a fundamental component of treating a variety of disorders. As surgical techniques have advanced the frequency of use of orthopaedic casts has declined. With Orthopaedics being is one of the most litigious specialties in medicine we sough to evaluate how this related to casting in Orthopaedics and how we could learn from past mistakes.We analysed litigation claims related to Orthopaedic casts from 1995 to 2010 in which the claims were closed. 43 cases were related to orthopaedic casts. The total costs of these claims were over £2.3 million with an average total cost of £48,500 per claim. The most common cause for claim was harm caused when a cast was applied too tight and secondly from removing the cast. This is the first study to evaluate litigation claims related to Orthopaedic casts and highlights potential complications that if avoided will certainly improve the care of the patients and avoid unnecessary litigation.     

手法复位石膏外固定联合盘龙七片治疗A3型桡骨远端骨折的早期疗效

目的探讨手法复位石膏外固定术联合口服盘龙七片治疗A3型桡骨远端骨折的早期疗效,为临床治疗提供参考。方法选取2018年6月至2020年1月于邳州医院治疗的A3型桡骨远端骨折患者100例,随机分为对照组(手法复位石膏外固定术,50例)和研究组(手法复位石膏外固定术联合口服盘龙七片,50例)。比较两组患者治疗前和治疗7 d血清IL-1、IL-6、TNF-α水平及治疗后4周Gartland-Werley腕关节评分,评价两组患者早期临床治疗效果。结果经过7 d治疗后,两组血清IL-1、IL-6、TNF-α水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05,P<0.01)。研究组患者拆除石膏后Gartland-Werley腕关节评分优良率高于对照组,差异有统计学意义(82.0%vs 48.0%,χ²=12.703,P<0.01)。结论手法复位石膏外固定术联合口服盘龙七片治疗A3型桡骨远端骨折,较之单纯手法复位石膏外固定能有效降低骨折炎性反应,缓解疼痛、肿胀。